J Korean Ophthalmol Soc.  2008 Jan;49(1):81-90. 10.3341/jkos.2008.49.1.81.

Intravitreal Versus Subtenon Injections of Triamcinolone Acetonide for Diabetic Macular Edema

Affiliations
  • 1Department of Ophthalmology, Kyungpook National University College of Medicine, Daegu, Korea. kimsy@knu.ac.kr

Abstract

PURPOSE: To retrospectively evaluate the clinical effect of intravitreal (IVT) and posterior subtenon (PSTT) triamcinolone acetonide (TA) injection in diabetic macular edema.
METHODS
Fifty eyes of 43 patients with diabetic macular edema (DME) were included. Twenty-two eyes in the IVT group received 4 mg/0.1 ml intravitreal TA injections and 26 eyes in the PSTT group received 40 mg/1.0 ml subtenon TA injections. LogMAR visual acuity and intraocular pressure (IOP) were measured and, using OCT, central macular thickness (CMT) and total macular volume (TMV) were also measured before and 1, 3, and 6 months postoperatively.
RESULTS
Both groups showed significant decreases in the mean CMT and TMV. The mean CMT in the IVT group was significantly thinner than that of the PSTT group 1 month postoperatively. The percentage reduction in CMT and TMV were also greater in the IVT group than the PSTT group 1 month postoperatively. Both groups showed significant improvements in mean visual acuity, with no significant difference between the two groups. However, at 1-month postoperative improvement in visual acuity was significantly greater in the IVT group than the PSTT group. The mean IOP in the IVT group was also greater than that in the PSTT 1 month postoperatively.
CONCLUSIONS
Both injections caused a significant increase in visual acuity and a decrease in CMT and TMV. The effect was more pronounced in the IVT group. However, the PSTT injection also appeared to be a safe and effective technique for the treatment of DME.

Keyword

Diabetic macular edema; Intravitreal injection; Posterior subtenon injection; Triamcinolone acetonide

MeSH Terms

Eye
Humans
Intraocular Pressure
Intravitreal Injections
Macular Edema
Retrospective Studies
Triamcinolone
Triamcinolone Acetonide
Visual Acuity
Triamcinolone
Triamcinolone Acetonide

Figure

  • Figure 1. Temporal changes of mean central macular thickness (CMT) in intravitreal TA injection (IVT) and subtenon TA injection (PSTT) groups.

  • Figure 2. Temporal changes of mean total macular volume (TMV) in intravitreal TA injection (IVT) and subtenon TA injection (PSTT) groups.

  • Figure 3. Comparison of mean percentage reduction in central macular thickness and total macular volume between intravitreal TA injection (IVT) and subtenon TA injection (PSTT) groups.

  • Figure 4. Temporal changes of mean visual acuity (logMAR) in intravitreal TA injection (IVT) and subtenon TA injection (PSTT) groups.


Cited by  2 articles

Combined Therapy of Intravitreal Bevacizumab and Posterior Subtenon Triamcinolone Acetonide Injection in Diabetic Macular Edema
Hoon Dong Kim, Kyung Seek Choi, Sung Jin Lee
J Korean Ophthalmol Soc. 2009;50(11):1652-1656.    doi: 10.3341/jkos.2009.50.11.1652.

Posterior Subtenon Triamcinolone Acetonide Injection for Refractory Diabetic Macular Edema in Vitrectomized Eye
Jung Hyun Lee, Hyun Jun Park, Ji Eun Lee, Boo Sup Oum
J Korean Ophthalmol Soc. 2011;52(7):832-837.    doi: 10.3341/jkos.2011.52.7.832.


Reference

References

1. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol. 1985; 103:1796–806.
2. Early Treatment Diabetic Retinopathy Study Research Group. Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study Report Number 2. Ophthalmology. 1987; 94:761–74.
3. Early Treatment Diabetic Retinopathy Study Research Group. Focal photocoagulation treatment of diabetic macular edema. Relationship of treatment effect to fluorescein angiographic and other retinal characteristics at baseline: ETDRS report no. 19. Arch Ophthalmol. 1995; 113:1144–55.
4. Martidis A, Duker JS, Greenberg PB, et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology. 2002; 109:920–7.
Article
5. Jonas JB, Kreissig I, Sofker A, Degenring RF. Intravitreal injection of triamcinolone for diffuse diabetic macular edema. Arch Ophthalmol. 2003; 121:57–61.
Article
6. Massin P, Aurden F, Haouchine B, et al. Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: preliminary results of a prospective controlled trial. Ophthalmology. 2004; 111:218–24.
7. Aurden F, Tod M, Massin P, et al. Pharmacokinetic- pharmacodynamic modeling of the effect of triamcinolone acetonide on central macular thickness in patients with diabetic macular edema. Invest Ophthalmol Vis Sci. 2004; 45:3435–41.
8. Sutter FK, Simpson JM, Gillies MC. Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: three-month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial. Ophthalmology. 2004; 111:2044–9.
9. Kim IC, Cho NC, Ahn M. Intravitreal Injection of Triamcinolone for Refractory Diabetic Macular Edema. J Korean Ophthalmol Soc. 2004; 45:228–36.
10. Moshfeghi DM, Kaiser PK, Scott IU, et al. Acute endophthalmitis following intravitreal triamcinolone acetonide injection. Am J Ophthalmol. 2003; 136:791–6.
Article
11. Benz MS, Murray TG, Dubovy SR, et al. Endophthalmitis caused by Mycobacterium chelonae abscessus after intravitreal injection of triamcinolone. Arch Ophthalmol. 2003; 121:271–3.
Article
12. Nelson ML, Tennant MT, Sivalingam A, et al. Infectious and presumed noninfectious endophthalmitis after intravitreal triamcinolone acetonide injection. Retina. 2003; 23:686–91.
Article
13. Park HJ, Park JM, Oum BS. Presumed Noninfectious Endophthalmitis after Intravitreal Injection of Triamcinolone Acetonide. J Korean Ophthalmol Soc. 2005; 46:1419–23.
14. Jonas JB, Sofker A, Degenring R. Intravitreal triamcinolone acetonide as an additional tool in pars plana vitrectomy for proliferative diabetic retinopathy. Eur J Ophthalmol. 2003; 13:468–73.
Article
15. Jonas JB, Kreissig I, Degenring R. Intraocular pressure after intravitreal injection of triamcinolone acetonide. Br J Ophthalmol. 2003; 87:24–7.
Article
16. Kaushik S, Gupta V, Gupta A, et al. Intractable glaucoma following intravitreal triamcinolone in central retinal vein occlusion. Am J Ophthalmol. 2004; 137:758–60.
Article
17. Melberg NS, Olk RJ. Corticosteroid-induced ocular hypertension in the treatment of aphakic or pseudophakic cystoid macular edema. Ophthalmology. 1993; 100:164–7.
Article
18. Helm CJ, Holland GN. The effects of posterior subtenon injection of triamcinolone acetonide in patients with intermediate uveitis. Am J Ophthalmol. 1995; 120:55–64.
Article
19. Tanner V, Kanski JJ, Frith PA. Posterior sub-Tenon’s triamcinolone injections in the treatment of uveitis. Eye. 1998; 12:679–85.
Article
20. Okada AA, Wakabayashi T, Morimura Y, et al. Trans-Tenon’s retrobulbar triamcinolone infusion for the treatment of uveitis. Br J Ophthalmol. 2003; 87:968–71.
Article
21. Cardillo JA, Melo LA Jr, Costa RA, et al. Comparison of intravitreal versus posterior sub-Tenon’s capsule injection of triamcinolone acetonide for diffuse diabetic macular edema. Ophthalmology. 2005; 112:1557–63.
Article
22. Bakri SJ, Kaiser PK. Posterior subtenon triamcinolone acetonide for refractory diabetic macular edema. Am J Ophthalmol. 2005; 139:290–4.
Article
23. Tunc M, Onder HI, Kaya M. Posterior sub-Tenon’s capsule triamcinolone injection combined with focal laser photocoagulation for diabetic macular edema. Ophthalmology. 2005; 112:1086–91.
Article
24. Hayashi K, Hayashi H. Intravitreal versus retrobulbar injections of triamcinolone for macular edema associated with branch retinal vein occlusion. Am J Ophthalmol. 2005; 139:972–82.
Article
25. Schindler RH, Chandler D, Thresher R, Machemer R. The clearance of intravitreal triamcinolone acetonide. Am J Ophthalmol. 1982; 93:415–7.
Article
26. Machemer R. Five cases in which a depot steroid (hydrocortisone acetate and methylprednisolone acetate) was injected into the eye. Retina. 1996; 16:166–7.
27. Challa JK, Gillies MC, Penfold PL, et al. Exudative macular degeneration and intravitreal triamcinolone: 18 month follow up. Aust N Z J Ophthalmol. 1998; 26:277–81.
Article
28. Danis RP, Ciulla TA, Pratt LM, Anliker W. Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. Retina. 2000; 20:244–50.
Article
29. Greenberg PB, Martidis A, Rogers AH, et al. Intravitreal triamcinolone acetonide for macular oedema due to central retinal vein occlusion. Br J Ophthalmol. 2002; 86:247–8.
Article
30. Antcliff RJ, Spalton DJ, Stanford MR, et al. Intravitreal triamcinolone for uveitic cystoid macular edema: an optical coherence tomography study. Ophthalmology. 2001; 108:765–72.
Article
31. Young S, Larkin G, Branley M, Lightman S. Safety and efficacy of intravitreal triamcinolone for cystoid macular oedema in uveitis. Clin Experiment Ophthalmol. 2001; 29:2–6.
Article
32. Benhamou N, Massin P, Haouchine B, et al. Intravitreal triamcinolone for refractory pseudophakic macular edema. Am J Ophthalmol. 2003; 135:246–9.
Article
33. Ciulla TA, Walker JD, Fong DS, et al. Corticosteroids in posterior segment disease: An update on new delivery systems and new indications. Curr Opin Ophthalmol. 2004; 15:211–20.
Article
34. McCuen BW 2nd, Bessler M, Tano Y, et al. The lack of toxicity of intravitreally administered triamcinolone acetonide. Am J Ophthalmol. 1981; 91:785–8.
Article
35. Bakri SJ, Beer PM. The effect of intravitreal triamcinolone acetonide on intraocular pressure. Ophthalmic Surg Lasers Imaging. 2003; 34:386–90.
Article
36. Jonas JB, Degenring RF, Kreissig I, et al. Intraocular pressure elevation after intravitreal triamcinolone acetonide injection. Ophthalmology. 2005; 112:593–8.
Article
37. Yang YH, Kim KR, Yang SW, Yim HB. The Effect of Intravitreal Triamcinolone Acetonide on Intraocular Pressure. J Korean Ophthalmol Soc. 2004; 45:1081–5.
38. Gillies MC, Simpson JM, Billson FA, et al. Safety of an intravitreal injection of triamcinolone: results from a randomized clinical trial. Arch Ophthalmol. 2004; 122:336–40.
39. Pitkanen L, Ranta VP, Moilanen H, Urtti A. Permeability of retinal pigment epithelium: effects of permeant molecular weight and lipophilicity. Invest Ophthalmol Vis Sci. 2005; 46:641–6.
40. Ambati J, Gragoudas ES, Miller JW, et al. Transscleral delivery of bioactive protein to the choroid and retina. Invest Ophthalmol Vis Sci. 2000; 41:1186–91.
41. Nozik RA. Periocular injection of steroids. Trans Am Acad Ophthalmol Otolaryngol. 1972; 76:695–705.
42. Kalina PH, Erie JC, Rosenbaum L. Biochemical quantification of triamcinolone in subconjunctival depots. Arch Ophthalmol. 1995; 113:867–9.
Article
43. Beer PM, Bakri SJ, Singh RJ, et al. Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology. 2003; 110:681–6.
Article
44. Mueller AJ, Jian G, Banker AS, et al. The effect of deep posterior subtenon injection of corticosteroids on intraocular pressure. Am J Ophthalmol. 1998; 125:158–63.
Article
45. Smithen LM, Ober MD, Maranan L, Spaide RF. Intravitreal triamcinolone acetonide and intraocular pressure. Am J Ophthalmol. 2004; 138:740–3.
Article
46. Abel AD, Carlson JA, Bakri S, Meyer DR. Sclerosing lipogranuloma of the orbit after periocular steroid injection. Ophthalmology. 2003; 110:1841–5.
47. Jordan DR, Brownstein S, Lee-Wing MW, Coupal D. Orbital mass following injection with depot corticosteroids. Can J Ophthalmol. 2001; 36:153–5.
Article
48. Moshfeghi DM, Lowder CY, Roth DB, Kaiser PK. Retinal and choroidal vascular occlusion after posterior sub-tenon triamcinolone injection. Am J Ophthalmol. 2002; 134:132–4.
Article
Full Text Links
  • JKOS
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr